Evidence map›Paper›PMID 31886217›Full record

ArticleBioMed research international2019

Investigation of the Clinical Significance and Prognostic Value of the lncRNA

Yuanyuan Nie, Yan Jiao, Yanqing Li, Wei Li

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yuanyuan NieStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, China.ORCID https://orcid.org/0000-0002-2774-6852
Yan JiaoDepartment of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, China.ORCID https://orcid.org/0000-0001-6914-7949
Yanqing LiDepartment of Pathophysiology, College of Basic Medical Sciences, Jilin University, Changchun, Jilin 130021, China.ORCID https://orcid.org/0000-0001-7030-5537
Wei LiStem Cell and Cancer Center, First Hospital, Jilin University, Changchun, Jilin 130061, China.ORCID https://orcid.org/0000-0002-9479-028X
Jilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A refined liver cancer staging system and effective prognostic prediction can help clinicians make optimized treatment decisions, which is essential in our fight against cancer and for improving the unsatisfying survival rate of liver cancer globally. The prognosis of liver cancer is not only related to tumor status, it is also affected by the patients' liver functions and the chosen treatment. Currently, several staging systems are being tested. Herein, we analyzed RNA-seq data from the TCGA database and identified a newly annotated lncRNA,

Indexed as

Databases, GeneticGene Expression Regulation, NeoplasticLiver NeoplasmsAgedDisease-Free SurvivalFemaleHumansMaleMiddle AgedRNA, Long NoncodingRNA, NeoplasmSurvival RateRNA, Long NoncodingRNA, Neoplasm

Identifiers

PMID31886217
PMCPMC6925724
OpenAlexW2982477353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.